

St. Jude LIFE

*Establishment of a Lifetime Cohort of Adults
Surviving Childhood Cancer*



Data Tables

St. Jude Children's
Research Hospital

April 30, 2020

Data Freeze

Released 3/8/2021


Data Tables and Figures for SJLIFE
Participants and Non-Participants
through April 30, 2020

Table of Contents

SJLIFE Combined Cohort Study Status April 30, 2020	2
SJLIFE Original Cohort Study Status April 30, 2020	3
SJLIFE Expansion Cohort Study Status April 30, 2020	4
Table 1 Combined Cohort: Demographic and Diagnostic Characteristics: Consented (N=6006)*	5
Table 1 Original Cohort: Demographic and Diagnostic Characteristics: Consented (N=3844)*	6
Table 1 Expansion Cohort: Demographic and Diagnostic Characteristics: Consented (N=2162)*	7
Table 2 Combined Cohort: Age and Follow-Up Characteristics: Consented (N=6006)*	8
Table 2 Original Cohort: Age and Follow-Up Characteristics: Consented (N=3844)*	9
Table 2 Expansion Cohort: Age and Follow-Up Characteristics: Consented (N=2162)*	10
Table 3 Combined Cohort. Demographic and Diagnostic Characteristics:	11
Table 3 Original Cohort. Demographic and Diagnostic Characteristics:	12
Table 3 Expansion. Demographic and Diagnostic Characteristics:	13
Table 4 Combined Cohort. Age and Follow-Up Characteristics:	14
Table 4 Original Cohort. Age and Follow-Up Characteristics:	15
Table 4 Expansion Cohort. Age and Follow-Up Characteristics:	16
Table 5a Combined Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Years from Diagnosis (N=5229)*	17
Table 5a Original Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Years from Diagnosis (N=3482)*	18
Table 5a Expansion Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Years from Diagnosis (N=1747)*	19
Table 5b Combined Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Age at Last Visit (N=5229)*	20
Table 5b Original Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Age at Last Visit (N=3482)*	21
Table 5b Expansion Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Age at Last Visit (N=1747)*	22
Table 6 Combined Cohort. Route and Chemotherapy Specific Percentile Dose Distributions.....	23
Table 6 Original Cohort. Route and Chemotherapy Specific Percentile Dose Distributions.....	29
Table 6 Expansion Cohort. Route and Chemotherapy Specific Percentile Dose Distributions.....	34
Table 7 Combined Cohort. Radiation Exposure among SJLIFE Campus Visit Participants	39
Table 7 Original Cohort. Radiation Exposure among SJLIFE Campus Visit Participants	40
Table 7 Expansion Cohort. Radiation Exposure among SJLIFE Campus Visit Participants	41


SJLIFE Combined Cohort Study Status

April 30, 2020



SJLIFE Original Cohort Study Status

April 30, 2020



SJLIFE Expansion Cohort Study Status

April 30, 2020




Table 1 Combined Cohort: Demographic and Diagnostic Characteristics: Consented (N=6006)*

Characteristic		Total N (%)	Campus Visit N (%)	Survey Only N (%)	Other N (%)
All Consented		6006	5229	302	475
Sex	Female	2875 (47.9)	2498 (47.8)	158 (52.3)	219 (46.1)
	Male	3131 (52.1)	2731 (52.2)	144 (47.7)	256 (53.9)
Race	White	4812 (80.1)	4204 (80.4)	264 (87.4)	344 (72.4)
	Black	993 (16.5)	852 (16.3)	36 (11.9)	105 (22.1)
	Other	201 (3.3)	173 (3.3)	2 (0.7)	26 (5.5)
Hispanic Ethnicity	Hispanic/Latino	237 (3.9)	205 (3.9)	0 (0.0)	32 (6.7)
	Non Hispanic/Latino	5720 (95.2)	4985 (95.3)	300 (99.3)	435 (91.6)
	Unknown	49 (0.8)	39 (0.7)	2 (0.7)	8 (1.7)
Primary Diagnosis	Acute lymphoblastic leukemia	1668 (27.8)	1485 (28.4)	81 (26.8)	102 (21.5)
	Acute myeloid leukemia	284 (4.7)	243 (4.6)	17 (5.6)	24 (5.1)
	Other leukemia	49 (0.8)	43 (0.8)	4 (1.3)	2 (0.4)
	Other hematologic malignancy	47 (0.8)	42 (0.8)	2 (0.7)	3 (0.6)
	CNS tumor	956 (15.9)	765 (14.6)	43 (14.2)	148 (31.2)
	Ewing sarcoma family of tumors	152 (2.5)	133 (2.5)	6 (2.0)	13 (2.7)
	Osteosarcoma	197 (3.3)	177 (3.4)	11 (3.6)	9 (1.9)
	Germ cell tumor	126 (2.1)	105 (2.0)	11 (3.6)	10 (2.1)
	Hepatoblastoma	43 (0.7)	37 (0.7)	2 (0.7)	4 (0.8)
	Hodgkin lymphoma	590 (9.8)	522 (10.0)	41 (13.6)	27 (5.7)
	Non-Hodgkin lymphoma	357 (5.9)	318 (6.1)	24 (7.9)	15 (3.2)
	Melanoma	57 (0.9)	46 (0.9)	2 (0.7)	9 (1.9)
	Neuroblastoma	268 (4.5)	249 (4.8)	6 (2.0)	13 (2.7)
	Retinoblastoma	357 (5.9)	308 (5.9)	10 (3.3)	39 (8.2)
	Rhabdomyosarcoma (RMS)	194 (3.2)	170 (3.3)	12 (4.0)	12 (2.5)
	Non-RMS	163 (2.7)	146 (2.8)	8 (2.6)	9 (1.9)
	Wilms tumor	352 (5.9)	312 (6.0)	17 (5.6)	23 (4.8)
	Carcinomas	85 (1.4)	72 (1.4)	5 (1.7)	8 (1.7)
	Other malignancy	41 (0.7)	38 (0.7)	0 (0.0)	3 (0.6)
	Other neoplasm	20 (0.3)	18 (0.3)	0 (0.0)	2 (0.4)

**Study status as of April 30, 2020*

Table 1 Original Cohort: Demographic and Diagnostic Characteristics: Consented (N=3844)*

Characteristic		Total N (%)	Campus Visit N (%)	Survey Only N (%)	Other N (%)
All Consented		3844	3482	284	78
Sex					
	Female	1824 (47.5)	1639 (47.1)	152 (53.5)	33 (42.3)
	Male	2020 (52.5)	1843 (52.9)	132 (46.5)	45 (57.7)
Race					
	White	3215 (83.6)	2905 (83.4)	249 (87.7)	61 (78.2)
	Black	563 (14.6)	513 (14.7)	34 (12.0)	16 (20.5)
	Other	66 (1.7)	64 (1.8)	1 (0.4)	1 (1.3)
Hispanic Ethnicity					
	Hispanic/Latino	86 (2.2)	83 (2.4)	0 (0.0)	3 (3.8)
	Non Hispanic/Latino	3742 (97.3)	3386 (97.2)	282 (99.3)	74 (94.9)
	Unknown	16 (0.4)	13 (0.4)	2 (0.7)	1 (1.3)
Primary Diagnosis					
	Acute lymphoblastic leukemia	1204 (31.3)	1107 (31.8)	79 (27.8)	18 (23.1)
	Acute myeloid leukemia	146 (3.8)	130 (3.7)	15 (5.3)	1 (1.3)
	Other leukemia	34 (0.9)	29 (0.8)	4 (1.4)	1 (1.3)
	Other hematologic malignancy	23 (0.6)	21 (0.6)	2 (0.7)	0 (0.0)
	CNS tumor	435 (11.3)	390 (11.2)	32 (11.3)	13 (16.7)
	Ewing sarcoma family of tumors	112 (2.9)	103 (3.0)	6 (2.1)	3 (3.8)
	Osteosarcoma	144 (3.7)	132 (3.8)	11 (3.9)	1 (1.3)
	Germ cell tumor	93 (2.4)	81 (2.3)	11 (3.9)	1 (1.3)
	Hepatoblastoma	29 (0.8)	26 (0.7)	2 (0.7)	1 (1.3)
	Hodgkin lymphoma	459 (11.9)	413 (11.9)	40 (14.1)	6 (7.7)
	Non-Hodgkin lymphoma	273 (7.1)	247 (7.1)	24 (8.5)	2 (2.6)
	Melanoma	25 (0.7)	20 (0.6)	2 (0.7)	3 (3.8)
	Neuroblastoma	166 (4.3)	156 (4.5)	6 (2.1)	4 (5.1)
	Retinoblastoma	117 (3.0)	102 (2.9)	10 (3.5)	5 (6.4)
	Rhabdomyosarcoma (RMS)	136 (3.5)	122 (3.5)	11 (3.9)	3 (3.8)
	Non-RMS	108 (2.8)	97 (2.8)	8 (2.8)	3 (3.8)
	Wilms tumor	256 (6.7)	228 (6.5)	16 (5.6)	12 (15.4)
	Carcinomas	57 (1.5)	52 (1.5)	5 (1.8)	0 (0.0)
	Other malignancy	22 (0.6)	21 (0.6)	0 (0.0)	1 (1.3)
	Other neoplasm	5 (0.1)	5 (0.1)	0 (0.0)	0 (0.0)

**Study status as of April 30, 2020*

Table 1 Expansion Cohort: Demographic and Diagnostic Characteristics: Consented (N=2162)*

Characteristic		Total N (%)	Campus Visit N (%)	Survey Only N (%)	Other N (%)
All Consented		2162	1747	18	397
Sex					
	Female	1051 (48.6)	859 (49.2)	6 (33.3)	186 (46.9)
	Male	1111 (51.4)	888 (50.8)	12 (66.7)	211 (53.1)
Race					
	White	1597 (73.9)	1299 (74.4)	15 (83.3)	283 (71.3)
	Black	430 (19.9)	339 (19.4)	2 (11.1)	89 (22.4)
	Other	135 (6.2)	109 (6.2)	1 (5.6)	25 (6.3)
Hispanic Ethnicity					
	Hispanic/Latino	151 (7.0)	122 (7.0)	0 (0.0)	29 (7.3)
	Non Hispanic/Latino	1978 (91.5)	1599 (91.5)	18 (100.0)	361 (90.9)
	Unknown	33 (1.5)	26 (1.5)	0 (0.0)	7 (1.8)
Primary Diagnosis					
	Acute lymphoblastic leukemia	464 (21.5)	378 (21.6)	2 (11.1)	84 (21.2)
	Acute myeloid leukemia	138 (6.4)	113 (6.5)	2 (11.1)	23 (5.8)
	Other leukemia	15 (0.7)	14 (0.8)	0 (0.0)	1 (0.3)
	Other hematologic malignancy	24 (1.1)	21 (1.2)	0 (0.0)	3 (0.8)
	CNS tumor	521 (24.1)	375 (21.5)	11 (61.1)	135 (34.0)
	Ewing sarcoma family of tumors	40 (1.9)	30 (1.7)	0 (0.0)	10 (2.5)
	Osteosarcoma	53 (2.5)	45 (2.6)	0 (0.0)	8 (2.0)
	Germ cell tumor	33 (1.5)	24 (1.4)	0 (0.0)	9 (2.3)
	Hepatoblastoma	14 (0.6)	11 (0.6)	0 (0.0)	3 (0.8)
	Hodgkin lymphoma	131 (6.1)	109 (6.2)	1 (5.6)	21 (5.3)
	Non-Hodgkin lymphoma	84 (3.9)	71 (4.1)	0 (0.0)	13 (3.3)
	Melanoma	32 (1.5)	26 (1.5)	0 (0.0)	6 (1.5)
	Neuroblastoma	102 (4.7)	93 (5.3)	0 (0.0)	9 (2.3)
	Retinoblastoma	240 (11.1)	206 (11.8)	0 (0.0)	34 (8.6)
	Rhabdomyosarcoma (RMS)	58 (2.7)	48 (2.7)	1 (5.6)	9 (2.3)
	Non-RMS	55 (2.5)	49 (2.8)	0 (0.0)	6 (1.5)
	Wilms tumor	96 (4.4)	84 (4.8)	1 (5.6)	11 (2.8)
	Carcinomas	28 (1.3)	20 (1.1)	0 (0.0)	8 (2.0)
	Other malignancy	19 (0.9)	17 (1.0)	0 (0.0)	2 (0.5)
	Other neoplasm	15 (0.7)	13 (0.7)	0 (0.0)	2 (0.5)

**Study status as of April 30, 2020*

Table 2 Combined Cohort: Age and Follow-Up Characteristics: Consented (N=6006)*

Characteristic		Total N (%)	Campus Visit N (%)	Survey Only N (%)	Other N (%)
Age at Diagnosis (Years)	Mean +/- sd	7.3 +/- 5.7	7.3 +/- 5.7	8.6 +/- 5.7	6.0 +/- 5.2
	Median	6.0	6.0	8.0	5.0
	Range	0.0-24.0	0.0-24.0	0.0-21.0	0.0-19.0
	<1	530 (8.8)	460 (8.8)	15 (5.0)	55 (11.6)
	01 - 04	2021 (33.6)	1763 (33.7)	77 (25.5)	181 (38.1)
	05 - 09	1323 (22.0)	1124 (21.5)	82 (27.2)	117 (24.6)
	10 - 14	1215 (20.2)	1072 (20.5)	66 (21.9)	77 (16.2)
	15 - 19	864 (14.4)	764 (14.6)	55 (18.2)	45 (9.5)
	20+	53 (0.9)	46 (0.9)	7 (2.3)	
Diagnosis to Visit/Survey/Enroll (Years)	Mean +/- sd		19.6 +/- 8.9	25.6 +/- 8.7	17.7 +/- 5.7
	Median		17.6	25.5	18.0
	Range		6.0-55.9	5.5-46.8	6.0-49.0
	05 - 09		649 (12.4)	10 (3.3)	47 (9.9)
	10 - 19		2440 (46.7)	72 (23.8)	275 (57.9)
	20 - 29		1360 (26.0)	125 (41.4)	143 (30.1)
	30 - 39		653 (12.5)	77 (25.5)	7 (1.5)
	40 - 44		95 (1.8)	15 (5.0)	2 (0.4)
	45 - 49		30 (0.6)	3 (1.0)	1 (0.2)
	50+		2 (0.0)		
Age at Visit/Survey/Enroll (Years)	Mean +/- sd		26.9 +/- 9.9	34.3 +/- 9.8	17.7 +/- 5.7
	Median		26.0	33.0	18.0
	Range		7.0-64.0	12.0-63.0	6.0-49.0
	05 - 09		114 (2.2)		47 (9.9)
	10 - 17		723 (13.8)	8 (2.6)	158 (33.3)
	18 - 24		1533 (29.3)	43 (14.2)	226 (47.6)
	25 - 29		954 (18.2)	53 (17.5)	34 (7.2)
	30 - 34		787 (15.1)	59 (19.5)	5 (1.1)
	35 - 39		516 (9.9)	43 (14.2)	2 (0.4)
	40 - 44		325 (6.2)	51 (16.9)	2 (0.4)
	45 - 49		175 (3.3)	25 (8.3)	1 (0.2)
	50 - 54		69 (1.3)	14 (4.6)	
	55 - 59		26 (0.5)	5 (1.7)	
	60+		7 (0.1)	1 (0.3)	

*Study status as of April 30, 2020

Table 2 Original Cohort: Age and Follow-Up Characteristics: Consented (N=3844)*

Characteristic		Total N (%)	Campus Visit N (%)	Survey Only N (%)	Other N (%)
Age at Diagnosis (Years)	Mean +/- sd	7.9 +/- 5.6	7.9 +/- 5.6	8.7 +/- 5.8	6.4 +/- 5.6
	Median	7.0	7.0	8.0	4.0
	Range	0.0-24.0	0.0-24.0	0.0-21.0	0.0-19.0
	<1	232 (6.0)	208 (6.0)	14 (4.9)	10 (12.8)
	01 - 04	1185 (30.8)	1079 (31.0)	76 (26.8)	30 (38.5)
	05 - 09	913 (23.8)	829 (23.8)	70 (24.6)	14 (17.9)
	10 - 14	878 (22.8)	800 (23.0)	64 (22.5)	14 (17.9)
	15 - 19	603 (15.7)	540 (15.5)	53 (18.7)	10 (12.8)
	20+	33 (0.9)	26 (0.7)	7 (2.5)	
Diagnosis to Visit/Survey/Enroll (Years)	Mean +/- sd		23.3 +/- 8.2	26.5 +/- 8.0	22.7 +/- 6.3
	Median		22.1	26.0	20.5
	Range		10.4-55.9	11.3-46.8	18.0-49.0
	10 - 19		1412 (40.6)	65 (22.9)	34 (43.6)
	20 - 29		1300 (37.3)	124 (43.7)	35 (44.9)
	30 - 39		649 (18.6)	77 (27.1)	6 (7.7)
	40 - 44		93 (2.7)	15 (5.3)	2 (2.6)
	45 - 49		27 (0.8)	3 (1.1)	1 (1.3)
	50+		1 (0.0)		
Age at Visit/Survey/Enroll (Years)	Mean +/- sd		31.1 +/- 8.4	35.2 +/- 9.1	22.7 +/- 6.3
	Median		30.0	34.0	20.5
	Range		18.0-64.0	18.0-63.0	18.0-49.0
	18 - 24		905 (26.0)	36 (12.7)	58 (74.4)
	25 - 29		751 (21.6)	50 (17.6)	11 (14.1)
	30 - 34		733 (21.1)	59 (20.8)	4 (5.1)
	35 - 39		504 (14.5)	43 (15.1)	2 (2.6)
	40 - 44		320 (9.2)	51 (18.0)	2 (2.6)
	45 - 49		172 (4.9)	25 (8.8)	1 (1.3)
	50 - 54		66 (1.9)	14 (4.9)	
	55 - 59		25 (0.7)	5 (1.8)	
	60+		6 (0.2)	1 (0.4)	

**Study status as of April 30, 2020*

Table 2 Expansion Cohort: Age and Follow-Up Characteristics: Consented (N=2162)*

Characteristic		Total N (%)	Campus Visit N (%)	Survey Only N (%)	Other N (%)
Age at Diagnosis (Years)	Mean +/- sd	6.2 +/- 5.7	6.2 +/- 5.9	7.7 +/- 4.1	5.9 +/- 5.1
	Median	4.0	4.0	7.0	5.0
	Range	0.0-24.0	0.0-24.0	0.0-16.0	0.0-19.0
	<1	298 (13.8)	252 (14.4)	1 (5.6)	45 (11.3)
	01 - 04	836 (38.7)	684 (39.2)	1 (5.6)	151 (38.0)
	05 - 09	410 (19.0)	295 (16.9)	12 (66.7)	103 (25.9)
	10 - 14	337 (15.6)	272 (15.6)	2 (11.1)	63 (15.9)
	15 - 19	261 (12.1)	224 (12.8)	2 (11.1)	35 (8.8)
	20+	20 (0.9)	20 (1.1)		
Diagnosis to Visit/Survey/Enroll (Years)	Mean +/- sd		12.1 +/- 4.4	11.2 +/- 4.7	16.7 +/- 5.1
	Median		11.2	9.4	17.0
	Range		6.0-52.5	5.5-21.3	6.0-30.0
	05 - 09		649 (37.1)	10 (55.6)	47 (11.8)
	10 - 19		1028 (58.8)	7 (38.9)	241 (60.7)
	20 - 29		60 (3.4)	1 (5.6)	108 (27.2)
	30 - 39		4 (0.2)		1 (0.3)
	40 - 44		2 (0.1)		
	45 - 49		3 (0.2)		
	50+		1 (0.1)		
Age at Visit/Survey/Enroll (Years)	Mean +/- sd		18.3 +/- 6.6	18.8 +/- 5.1	16.7 +/- 5.1
	Median		18.0	18.0	17.0
	Range		7.0-64.0	12.0-28.0	6.0-30.0
	05 - 09		114 (6.5)		47 (11.8)
	10 - 17		723 (41.4)	8 (44.4)	158 (39.8)
	18 - 24		628 (35.9)	7 (38.9)	168 (42.3)
	25 - 29		203 (11.6)	3 (16.7)	23 (5.8)
	30 - 34		54 (3.1)		1 (0.3)
	35 - 39		12 (0.7)		
	40 - 44		5 (0.3)		
	45 - 49		3 (0.2)		
	50 - 54		3 (0.2)		
	55 - 59		1 (0.1)		
	60+		1 (0.1)		

*Study status as of April 30, 2020

**Table 3 Combined Cohort. Demographic and Diagnostic Characteristics:
Consented (N=6006), Interested (N=550), Non-Participants (N=911)***

Characteristic		Total N (%)	Consented Population N (%)	Non- Participants N (%)	Interested N (%)
All		7467	6006	911	550
Sex	Female	3452 (46.2)	2875 (47.9)	358 (39.3)	219 (39.8)
	Male	4015 (53.8)	3131 (52.1)	553 (60.7)	331 (60.2)
Race	White	5960 (79.8)	4812 (80.1)	725 (79.6)	423 (76.9)
	Black	1260 (16.9)	993 (16.5)	151 (16.6)	116 (21.1)
	Other	247 (3.3)	201 (3.3)	35 (3.8)	11 (2.0)
Hispanic Ethnicity	Hispanic/Latino	289 (3.9)	237 (3.9)	41 (4.5)	11 (2.0)
	Non Hispanic/Latino	7097 (95.0)	5720 (95.2)	846 (92.9)	531 (96.5)
	Unknown	81 (1.1)	49 (0.8)	24 (2.6)	8 (1.5)
Primary Diagnosis	Acute lymphoblastic leukemia	2068 (27.7)	1668 (27.8)	269 (29.5)	131 (23.8)
	Acute myeloid leukemia	362 (4.8)	284 (4.7)	46 (5.0)	32 (5.8)
	Other leukemia	64 (0.9)	49 (0.8)	9 (1.0)	6 (1.1)
	Other hematologic malignancy	69 (0.9)	47 (0.8)	14 (1.5)	8 (1.5)
	CNS tumor	1144 (15.3)	956 (15.9)	92 (10.1)	96 (17.5)
	Ewing sarcoma family of tumors	182 (2.4)	152 (2.5)	22 (2.4)	8 (1.5)
	Osteosarcoma	237 (3.2)	197 (3.3)	23 (2.5)	17 (3.1)
	Germ cell tumor	167 (2.2)	126 (2.1)	26 (2.9)	15 (2.7)
	Hepatoblastoma	61 (0.8)	43 (0.7)	9 (1.0)	9 (1.6)
	Hodgkin lymphoma	720 (9.6)	590 (9.8)	92 (10.1)	38 (6.9)
	Non-Hodgkin lymphoma	480 (6.4)	357 (5.9)	80 (8.8)	43 (7.8)
	Melanoma	72 (1.0)	57 (0.9)	7 (0.8)	8 (1.5)
	Neuroblastoma	342 (4.6)	268 (4.5)	49 (5.4)	25 (4.5)
	Retinoblastoma	410 (5.5)	357 (5.9)	29 (3.2)	24 (4.4)
	Rhabdomyosarcoma (RMS)	246 (3.3)	194 (3.2)	32 (3.5)	20 (3.6)
	Non-RMS	221 (3.0)	163 (2.7)	24 (2.6)	34 (6.2)
	Wilms tumor	437 (5.9)	352 (5.9)	60 (6.6)	25 (4.5)
	Carcinomas	110 (1.5)	85 (1.4)	16 (1.8)	9 (1.6)
	Other malignancy	46 (0.6)	41 (0.7)	4 (0.4)	1 (0.2)
	Other neoplasm	28 (0.4)	19 (0.3)	8 (0.9)	1 (0.2)

**Study status as of April 30, 2020*

**Table 3 Original Cohort. Demographic and Diagnostic Characteristics:
Consented (N=3844), Interested (N=337), Non-Participants (N=713)***

Characteristic		Total N (%)	Consented Population N (%)	Non- Participants N (%)	Interested N (%)
All		4894	3844	713	337
Sex	Female	2236 (45.7)	1824 (47.5)	282 (39.6)	130 (38.6)
	Male	2658 (54.3)	2020 (52.5)	431 (60.4)	207 (61.4)
Race	White	4084 (83.4)	3215 (83.6)	591 (82.9)	278 (82.5)
	Black	722 (14.8)	563 (14.6)	102 (14.3)	57 (16.9)
	Other	88 (1.8)	66 (1.7)	20 (2.8)	2 (0.6)
Hispanic Ethnicity	Hispanic/Latino	117 (2.4)	86 (2.2)	27 (3.8)	4 (1.2)
	Non Hispanic/Latino	4741 (96.9)	3742 (97.3)	668 (93.7)	331 (98.2)
	Unknown	36 (0.7)	16 (0.4)	18 (2.5)	2 (0.6)
Primary Diagnosis	Acute lymphoblastic leukemia	1526 (31.2)	1204 (31.3)	229 (32.1)	93 (27.6)
	Acute myeloid leukemia	194 (4.0)	146 (3.8)	32 (4.5)	16 (4.7)
	Other leukemia	44 (0.9)	34 (0.9)	6 (0.8)	4 (1.2)
	Other hematologic malignancy	32 (0.7)	23 (0.6)	8 (1.1)	1 (0.3)
	CNS tumor	532 (10.9)	435 (11.3)	59 (8.3)	38 (11.3)
	Ewing sarcoma family of tumors	136 (2.8)	112 (2.9)	18 (2.5)	6 (1.8)
	Osteosarcoma	177 (3.6)	144 (3.7)	20 (2.8)	13 (3.9)
	Germ cell tumor	122 (2.5)	93 (2.4)	19 (2.7)	10 (3.0)
	Hepatoblastoma	42 (0.9)	29 (0.8)	6 (0.8)	7 (2.1)
	Hodgkin lymphoma	564 (11.5)	459 (11.9)	79 (11.1)	26 (7.7)
	Non-Hodgkin lymphoma	377 (7.7)	273 (7.1)	72 (10.1)	32 (9.5)
	Melanoma	37 (0.8)	25 (0.7)	6 (0.8)	6 (1.8)
	Neuroblastoma	218 (4.5)	166 (4.3)	38 (5.3)	14 (4.2)
	Retinoblastoma	142 (2.9)	117 (3.0)	16 (2.2)	9 (2.7)
	Rhabdomyosarcoma (RMS)	174 (3.6)	136 (3.5)	24 (3.4)	14 (4.2)
	Non-RMS	146 (3.0)	108 (2.8)	18 (2.5)	20 (5.9)
	Wilms tumor	324 (6.6)	256 (6.7)	46 (6.5)	22 (6.5)
	Carcinomas	73 (1.5)	57 (1.5)	11 (1.5)	5 (1.5)
	Other malignancy	26 (0.5)	22 (0.6)	3 (0.4)	1 (0.3)
	Other neoplasm	8 (0.2)	5 (0.1)	3 (0.4)	0 (0.0)

*Study status as of April 30, 2020

**Table 3 Expansion. Demographic and Diagnostic Characteristics:
Consented (N=2162), Interested (N=213), Non-Participants (N=198)***

Characteristic		Total N (%)	Consented Population N (%)	Non- Participants N (%)	Interested N (%)
All		2573	2162	198	213
Sex	Female	1216 (47.3)	1051 (48.6)	76 (38.4)	89 (41.8)
	Male	1357 (52.7)	1111 (51.4)	122 (61.6)	124 (58.2)
Race	White	1876 (72.9)	1597 (73.9)	134 (67.7)	145 (68.1)
	Black	538 (20.9)	430 (19.9)	49 (24.7)	59 (27.7)
	Other	159 (6.2)	135 (6.2)	15 (7.6)	9 (4.2)
Hispanic Ethnicity	Hispanic/Latino	172 (6.7)	151 (7.0)	14 (7.1)	7 (3.3)
	Non Hispanic/Latino	2356 (91.6)	1978 (91.5)	178 (89.9)	200 (93.9)
	Unknown	45 (1.7)	33 (1.5)	6 (3.0)	6 (2.8)
Primary Diagnosis	Acute lymphoblastic leukemia	542 (21.1)	464 (21.5)	40 (20.2)	38 (17.8)
	Acute myeloid leukemia	168 (6.5)	138 (6.4)	14 (7.1)	16 (7.5)
	Other leukemia	20 (0.8)	15 (0.7)	3 (1.5)	2 (0.9)
	Other hematologic malignancy	37 (1.4)	24 (1.1)	6 (3.0)	7 (3.3)
	CNS tumor	612 (23.8)	521 (24.1)	33 (16.7)	58 (27.2)
	Ewing sarcoma family of tumors	46 (1.8)	40 (1.9)	4 (2.0)	2 (0.9)
	Osteosarcoma	60 (2.3)	53 (2.5)	3 (1.5)	4 (1.9)
	Germ cell tumor	45 (1.7)	33 (1.5)	7 (3.5)	5 (2.3)
	Hepatoblastoma	19 (0.7)	14 (0.6)	3 (1.5)	2 (0.9)
	Hodgkin lymphoma	156 (6.1)	131 (6.1)	13 (6.6)	12 (5.6)
	Non-Hodgkin lymphoma	103 (4.0)	84 (3.9)	8 (4.0)	11 (5.2)
	Melanoma	35 (1.4)	32 (1.5)	1 (0.5)	2 (0.9)
	Neuroblastoma	124 (4.8)	102 (4.7)	11 (5.6)	11 (5.2)
	Retinoblastoma	268 (10.4)	240 (11.1)	13 (6.6)	15 (7.0)
	Rhabdomyosarcoma (RMS)	72 (2.8)	58 (2.7)	8 (4.0)	6 (2.8)
	Non-RMS	75 (2.9)	55 (2.5)	6 (3.0)	14 (6.6)
	Wilms tumor	113 (4.4)	96 (4.4)	14 (7.1)	3 (1.4)
	Carcinomas	37 (1.4)	28 (1.3)	5 (2.5)	4 (1.9)
	Other malignancy	20 (0.8)	19 (0.9)	1 (0.5)	0 (0.0)
	Other neoplasm	20 (0.8)	14 (0.6)	5 (2.5)	1 (0.5)

*Study status as of April 30, 2020

**Table 4 Combined Cohort. Age and Follow-Up Characteristics:
Consented (N=6006), Interested (N=550), Non-Participants (N=911)***

Characteristic		Total N (%)	Consented Population N (%)	Non- Participants N (%)	Interested N (%)
Years from Diagnosis as of April 30, 2020	Mean +/- sd	26.0 +/- 11.5	25.3 +/- 11.6	30.1 +/- 10.9	25.9 +/- 10.3
	Median	24.7	23.8	29.9	24.2
	Range	7.8-58.1	7.8-58.1	7.9-56.9	8.1-53.9
	05 - 09	433 (5.8)	398 (6.6)	15 (1.6)	20 (3.6)
	10 - 19	2327 (31.2)	1976 (32.9)	182 (20.0)	169 (30.7)
	20 - 29	2020 (27.1)	1576 (26.2)	264 (29.0)	180 (32.7)
	30 - 39	1638 (21.9)	1252 (20.8)	262 (28.8)	124 (22.5)
	40 - 44	570 (7.6)	437 (7.3)	102 (11.2)	31 (5.6)
	45 - 49	313 (4.2)	244 (4.1)	51 (5.6)	18 (3.3)
	50+	165 (2.2)	122 (2.0)	35 (3.8)	8 (1.5)
Age at Diagnosis (Years)	Mean +/- sd	7.3 +/- 5.7	7.3 +/- 5.7	7.5 +/- 5.6	7.9 +/- 5.8
	Median	6.0	6.0	6.0	7.0
	Range	0.0-28.0	0.0-24.0	0.0-28.0	0.0-20.0
	<1	643 (8.6)	530 (8.8)	68 (7.5)	45 (8.2)
	01 - 04	2487 (33.3)	2021 (33.7)	296 (32.5)	170 (30.9)
	05 - 09	1659 (22.2)	1323 (22.0)	222 (24.4)	114 (20.7)
	10 - 14	1501 (20.1)	1214 (20.2)	173 (19.0)	114 (20.7)
	15 - 19	1112 (14.9)	864 (14.4)	147 (16.1)	101 (18.4)
	20+	64 (0.9)	53 (0.9)	5 (0.5)	6 (1.1)
Age as of April 30, 2020	Mean +/- sd	33.3 +/- 12.4	32.6 +/- 12.6	37.5 +/- 11.1	33.8 +/- 10.6
	Median	33.0	32.0	37.0	32.0
	Range	8.0-75.0	8.0-73.0	9.0-75.0	9.0-72.0
	05 - 09	44 (0.6)	42 (0.7)	1 (0.1)	1 (0.2)
	10 - 17	741 (9.9)	704 (11.7)	20 (2.2)	17 (3.1)
	18 - 24	1212 (16.2)	1016 (16.9)	100 (11.0)	96 (17.5)
	25 - 29	1082 (14.5)	854 (14.2)	115 (12.6)	113 (20.5)
	30 - 34	1030 (13.8)	797 (13.3)	144 (15.8)	89 (16.2)
	35 - 39	998 (13.4)	796 (13.3)	134 (14.7)	68 (12.4)
	40 - 44	877 (11.7)	665 (11.1)	145 (15.9)	67 (12.2)
	45 - 49	675 (9.0)	498 (8.3)	126 (13.8)	51 (9.3)
	50 - 54	434 (5.8)	338 (5.6)	58 (6.4)	38 (6.9)
	55 - 59	245 (3.3)	192 (3.2)	48 (5.3)	5 (0.9)
	60+	129 (1.7)	104 (1.7)	20 (2.2)	5 (0.9)

*Study status as of April 30, 2020

**Table 4 Original Cohort. Age and Follow-Up Characteristics:
Consented (N=3844), Interested (N=337), Non-Participants (N=713)***

Characteristic		Total N (%)	Consented Population N (%)	Non- Participants N (%)	Interested N (%)
Years from Diagnosis as of April 30, 2020	Mean +/- sd	31.9 +/- 9.2	31.8 +/- 9.2	33.3 +/- 9.1	30.9 +/- 8.8
	Median	31.2	30.9	32.7	30.4
	Range	15.1-58.1	15.2-58.1	15.1-56.9	15.5-53.9
	10 - 19	485 (9.9)	389 (10.1)	54 (7.6)	42 (12.5)
	20 - 29	1764 (36.0)	1412 (36.7)	227 (31.8)	125 (37.1)
	30 - 39	1617 (33.0)	1246 (32.4)	253 (35.5)	118 (35.0)
	40 - 44	566 (11.6)	437 (11.4)	99 (13.9)	30 (8.9)
	45 - 49	303 (6.2)	239 (6.2)	47 (6.6)	17 (5.0)
	50+	159 (3.2)	121 (3.1)	33 (4.6)	5 (1.5)
Age at Diagnosis (Years)	Mean +/- sd	7.8 +/- 5.6	7.9 +/- 5.6	7.5 +/- 5.6	7.6 +/- 5.4
	Median	7.0	7.0	6.0	7.0
	Range	0.0-28.0	0.0-24.0	0.0-28.0	0.0-20.0
	<1	306 (6.3)	232 (6.0)	51 (7.2)	23 (6.8)
	01 - 04	1521 (31.1)	1185 (30.8)	232 (32.5)	104 (30.9)
	05 - 09	1172 (23.9)	913 (23.8)	181 (25.4)	78 (23.1)
	10 - 14	1095 (22.4)	878 (22.8)	135 (18.9)	82 (24.3)
	15 - 19	761 (15.5)	603 (15.7)	111 (15.6)	47 (13.9)
	20+	39 (0.8)	33 (0.9)	3 (0.4)	3 (0.9)
Age as of April 30, 2020	Mean +/- sd	39.7 +/- 9.5	39.6 +/- 9.5	40.8 +/- 9.5	38.5 +/- 9.3
	Median	39.0	38.0	40.0	38.0
	Range	23.0-75.0	23.0-73.0	23.0-75.0	23.0-72.0
	18 - 24	104 (2.1)	68 (1.8)	20 (2.8)	16 (4.7)
	25 - 29	645 (13.2)	529 (13.8)	64 (9.0)	52 (15.4)
	30 - 34	865 (17.7)	687 (17.9)	123 (17.3)	55 (16.3)
	35 - 39	970 (19.8)	781 (20.3)	126 (17.7)	63 (18.7)
	40 - 44	855 (17.5)	656 (17.1)	138 (19.4)	61 (18.1)
	45 - 49	661 (13.5)	494 (12.9)	121 (17.0)	46 (13.6)
	50 - 54	425 (8.7)	336 (8.7)	55 (7.7)	34 (10.1)
	55 - 59	242 (4.9)	190 (4.9)	47 (6.6)	5 (1.5)
	60+	127 (2.6)	103 (2.7)	19 (2.7)	5 (1.5)

*Study status as of April 30, 2020

**Table 4 Expansion Cohort. Age and Follow-Up Characteristics:
Consented (N=2162), Interested (N=213), Non-Participants (N=198)***

Characteristic		Total N (%)	Consented Population N (%)	Non- Participants N (%)	Interested N (%)
Years from Diagnosis as of April 30, 2020	Mean +/- sd	14.6 +/- 5.4	13.9 +/- 4.4	18.4 +/- 8.7	18.1 +/- 7.3
	Median	13.7	13.3	16.5	16.9
	Range	7.8-56.7	7.8-54.5	7.9-56.7	8.1-53.8
	05 - 09	433 (16.8)	398 (18.4)	15 (7.6)	20 (9.4)
	10 - 19	1842 (71.6)	1587 (73.4)	128 (64.6)	127 (59.6)
	20 - 29	256 (10.0)	164 (7.6)	37 (18.7)	55 (25.8)
	30 - 39	21 (0.8)	6 (0.3)	9 (4.5)	6 (2.8)
	40 - 44	4 (0.2)		3 (1.5)	1 (0.5)
	45 - 49	10 (0.4)	5 (0.2)	4 (2.0)	1 (0.5)
	50+	6 (0.2)	1 (0.0)	2 (1.0)	3 (1.4)
Age at Diagnosis (Years)	Mean +/- sd	6.5 +/- 5.8	6.2 +/- 5.7	7.5 +/- 5.9	8.2 +/- 6.4
	Median	4.0	4.0	6.0	6.0
	Range	0.0-24.0	0.0-24.0	0.0-21.0	0.0-20.0
	<1	337 (13.1)	298 (13.8)	17 (8.6)	22 (10.3)
	01 - 04	966 (37.6)	836 (38.7)	64 (32.3)	66 (31.0)
	05 - 09	487 (18.9)	410 (19.0)	41 (20.7)	36 (16.9)
	10 - 14	406 (15.8)	336 (15.5)	38 (19.2)	32 (15.0)
	15 - 19	351 (13.6)	261 (12.1)	36 (18.2)	54 (25.4)
	20+	25 (1.0)	20 (0.9)	2 (1.0)	3 (1.4)
Age as of April 30, 2020	Mean +/- sd	21.1 +/- 7.0	20.1 +/- 6.4	25.9 +/- 8.5	26.2 +/- 7.8
	Median	21.0	20.0	24.0	25.0
	Range	8.0-66.0	8.0-66.0	9.0-61.0	9.0-54.0
	05 - 09	44 (1.7)	42 (1.9)	1 (0.5)	1 (0.5)
	10 - 17	741 (28.8)	704 (32.6)	20 (10.1)	17 (8.0)
	18 - 24	1108 (43.1)	948 (43.8)	80 (40.4)	80 (37.6)
	25 - 29	437 (17.0)	325 (15.0)	51 (25.8)	61 (28.6)
	30 - 34	165 (6.4)	110 (5.1)	21 (10.6)	34 (16.0)
	35 - 39	28 (1.1)	15 (0.7)	8 (4.0)	5 (2.3)
	40 - 44	22 (0.9)	9 (0.4)	7 (3.5)	6 (2.8)
	45 - 49	14 (0.5)	4 (0.2)	5 (2.5)	5 (2.3)
	50 - 54	9 (0.3)	2 (0.1)	3 (1.5)	4 (1.9)
	55 - 59	3 (0.1)	2 (0.1)	1 (0.5)	
	60+	2 (0.1)	1 (0.0)	1 (0.5)	

**Study status as of April 30, 2020*

**Table 5a Combined Cohort. SJLIFE Campus Visit Participants
by Primary Diagnosis and Years from Diagnosis (N=5229)***

Primary Diagnosis	Years from Diagnosis as of April 30, 2020							Total
	05 - 09	10 - 19	20 - 29	30 - 39	40 - 44	45 - 49	50+	
Acute lymphoblastic leukemia	61	359	364	415	149	88	49	1485
Acute myeloid leukemia	19	106	73	28	14	3	.	243
Other leukemia	2	16	19	5	.	.	1	43
Other hematologic malignancy	2	14	7	9	5	4	1	42
CNS tumor	44	383	264	68	2	3	1	765
Ewing sarcoma family of tumors	6	38	39	34	11	3	2	133
Osteosarcoma	14	50	39	47	17	7	3	177
Germ cell tumor	5	22	38	28	8	3	1	105
Hepatoblastoma	2	9	9	12	1	3	1	37
Hodgkin lymphoma	20	146	148	122	42	32	12	522
Non-Hodgkin lymphoma	16	83	78	97	31	5	8	318
Melanoma	10	20	9	2	3	1	1	46
Neuroblastoma	15	69	50	65	27	18	5	249
Retinoblastoma	32	153	48	30	22	18	5	308
RMS	5	55	43	40	17	7	3	170
Non-RMS	4	50	54	29	2	6	1	146
Wilms tumor	10	65	83	93	33	14	14	312
Carcinomas	4	25	24	12	4	3	.	72
Other malignancy	2	17	15	1	2	1	.	38
Other neoplasm	1	12	4	1	.	.	.	18
Total	274	1692	1408	1138	390	219	108	5229

**Study status as of April 30, 2020*

Table 5a Original Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Years from Diagnosis (N=3482)*

Primary Diagnosis	Years from Diagnosis as of April 30, 2020						Total
	10 - 19	20 - 29	30 - 39	40 - 44	45 - 49	50+	
Acute lymphoblastic leukemia	70	337	415	149	87	49	1107
Acute myeloid leukemia	21	64	28	14	3	.	130
Other leukemia	4	19	5	.	.	1	29
Other hematologic malignancy	2	4	7	5	3	.	21
CNS tumor	86	234	64	2	3	1	390
Ewing sarcoma family of tumors	17	36	34	11	3	2	103
Osteosarcoma	20	39	47	17	6	3	132
Germ cell tumor	6	35	28	8	3	1	81
Hepatoblastoma	.	9	12	1	3	1	26
Hodgkin lymphoma	60	145	122	42	32	12	413
Non-Hodgkin lymphoma	29	77	97	31	5	8	247
Melanoma	5	8	2	3	1	1	20
Neuroblastoma	2	40	65	27	17	5	156
Retinoblastoma	2	26	30	22	17	5	102
RMS	15	40	40	17	7	3	122
Non-RMS	10	49	29	2	6	1	97
Wilms tumor	3	71	93	33	14	14	228
Carcinomas	11	22	12	4	3	.	52
Other malignancy	5	12	1	2	1	.	21
Other neoplasm	.	4	1	.	.	.	5
Total	368	1271	1132	390	214	107	3482

**Study status as of April 30, 2020*

Table 5a Expansion Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Years from Diagnosis (N=1747)*

Primary Diagnosis	Years from Diagnosis as of April 30, 2020						Total
	05 - 09	10 - 19	20 - 29	30 - 39	45 - 49	50+	
Acute lymphoblastic leukemia	61	289	27	.	1	.	378
Acute myeloid leukemia	19	85	9	.	.	.	113
Other leukemia	2	12	.	.	.	.	14
Other hematologic malignancy	2	12	3	2	1	1	21
CNS tumor	44	297	30	4	.	.	375
Ewing sarcoma family of tumors	6	21	3	.	.	.	30
Osteosarcoma	14	30	.	.	1	.	45
Germ cell tumor	5	16	3	.	.	.	24
Hepatoblastoma	2	9	.	.	.	.	11
Hodgkin lymphoma	20	86	3	.	.	.	109
Non-Hodgkin lymphoma	16	54	1	.	.	.	71
Melanoma	10	15	1	.	.	.	26
Neuroblastoma	15	67	10	.	1	.	93
Retinoblastoma	32	151	22	.	1	.	206
RMS	5	40	3	.	.	.	48
Non-RMS	4	40	5	.	.	.	49
Wilms tumor	10	62	12	.	.	.	84
Carcinomas	4	14	2	.	.	.	20
Other malignancy	2	12	3	.	.	.	17
Other neoplasm	1	12	.	.	.	.	13
Total	274	1324	137	6	5	1	1747

**Study status as of April 30, 2020*

Table 5b Combined Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Age at Last Visit (N=5229)*

Primary Diagnosis	Age at Last Visit											Total
	05 - 09	10 - 17	18 - 24	25 - 29	30 - 34	35 - 39	40 - 44	45 - 49	50 - 54	55 - 59	60+	
Acute lymphoblastic leukemia	9	182	253	236	219	219	147	122	69	21	8	1485
Acute myeloid leukemia	9	44	55	46	36	16	19	9	9	.	.	243
Other leukemia	.	5	10	3	12	5	4	1	3	.	.	43
Other hematologic malignancy	1	10	8	2	7	4	5	3	1	1	.	42
CNS tumor	11	123	252	178	113	62	20	3	1	2	.	765
Ewing sarcoma family of tumors	1	5	22	21	25	18	15	13	6	5	2	133
Osteosarcoma	.	3	35	22	21	23	20	21	20	6	6	177
Germ cell tumor	2	7	24	18	12	14	16	5	5	1	1	105
Hepatoblastoma	2	8	6	7	6	3	2	3	.	.	.	37
Hodgkin lymphoma	.	8	49	87	86	74	72	63	51	23	9	522
Non-Hodgkin lymphoma	.	18	51	46	49	47	43	36	20	6	2	318
Melanoma	1	11	18	4	5	1	2	.	2	1	1	46
Neuroblastoma	10	55	53	32	38	24	19	12	4	2	.	249
Retinoblastoma	40	120	58	19	19	19	16	15	1	1	.	308
RMS	1	23	34	24	26	26	17	8	7	3	1	170
Non-RMS	1	14	28	31	24	18	13	12	3	1	1	146
Wilms tumor	1	49	63	39	59	46	26	16	6	7	.	312
Carcinomas	.	3	18	10	12	10	10	5	3	1	.	72
Other malignancy	.	7	9	8	4	3	4	1	.	2	.	38
Other neoplasm	1	6	6	1	2	2	.	.	.	.	.	18
Total	90	701	1052	834	775	634	470	348	211	83	31	5229

**Study status as of April 30, 2020*

Table 5b Original Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Age at Last Visit (N=3482)*

Primary Diagnosis	Age at Last Visit									Total
	18 - 24	25 - 29	30 - 34	35 - 39	40 - 44	45 - 49	50 - 54	55 - 59	60+	
Acute lymphoblastic leukemia	110	199	214	219	146	122	68	21	8	1107
Acute myeloid leukemia	17	31	29	16	19	9	9	.	.	130
Other leukemia	6	1	9	5	4	1	3	.	.	29
Other hematologic malignancy	3	1	6	4	5	2	.	.	.	21
CNS tumor	84	128	98	58	17	2	1	2	.	390
Ewing sarcoma family of tumors	9	11	24	18	15	13	6	5	2	103
Osteosarcoma	5	15	18	22	20	21	20	6	5	132
Germ cell tumor	9	18	12	14	16	5	5	1	1	81
Hepatoblastoma	5	7	6	3	2	3	.	.	.	26
Hodgkin lymphoma	6	42	76	71	72	63	51	23	9	413
Non-Hodgkin lymphoma	16	31	46	47	43	36	20	6	2	247
Melanoma	5	3	5	1	2	.	2	1	1	20
Neuroblastoma	27	31	38	24	19	11	4	2	.	156
Retinoblastoma	13	19	19	19	16	15	.	1	.	102
RMS	15	22	25	24	17	8	7	3	1	122
Non-RMS	10	21	20	17	12	12	3	1	1	97
Wilms tumor	31	38	58	46	26	16	6	7	.	228
Carcinomas	6	7	11	9	10	5	3	1	.	52
Other malignancy	1	6	4	3	4	1	.	2	.	21
Other neoplasm	1	1	1	2	.	.	.	.	.	5
Total	379	632	719	622	465	345	208	82	30	3482

**Study status as of April 30, 2020*

Table 5b Expansion Cohort. SJLIFE Campus Visit Participants by Primary Diagnosis and Age at Last Visit (N=1747)*

Primary Diagnosis	Age at Last Visit											Total
	05 - 09	10 - 17	18 - 24	25 - 29	30 - 34	35 - 39	40 - 44	45 - 49	50 - 54	55 - 59	60+	
Acute lymphoblastic leukemia	9	182	143	37	5	.	1	.	1	.	.	378
Acute myeloid leukemia	9	44	38	15	7	.	.	.	.	.	.	113
Other leukemia	.	5	4	2	3	.	.	.	.	.	.	14
Other hematologic malignancy	1	10	5	1	1	.	.	1	1	1	.	21
CNS tumor	11	123	168	50	15	4	3	1	.	.	.	375
Ewing sarcoma family of tumors	1	5	13	10	1	.	.	.	.	.	.	30
Osteosarcoma	.	3	30	7	3	1	.	.	.	.	1	45
Germ cell tumor	2	7	15	.	.	.	.	.	.	.	.	24
Hepatoblastoma	2	8	1	.	.	.	.	.	.	.	.	11
Hodgkin lymphoma	.	8	43	45	10	3	.	.	.	.	.	109
Non-Hodgkin lymphoma	.	18	35	15	3	.	.	.	.	.	.	71
Melanoma	1	11	13	1	.	.	.	.	.	.	.	26
Neuroblastoma	10	55	26	1	.	.	.	1	.	.	.	93
Retinoblastoma	40	120	45	.	.	.	.	.	1	.	.	206
RMS	1	23	19	2	1	2	.	.	.	.	.	48
Non-RMS	1	14	18	10	4	1	1	.	.	.	.	49
Wilms tumor	1	49	32	1	1	.	.	.	.	.	.	84
Carcinomas	.	3	12	3	1	1	.	.	.	.	.	20
Other malignancy	.	7	8	2	.	.	.	.	.	.	.	17
Other neoplasm	1	6	5	.	1	.	.	.	.	.	.	13
Total	90	701	673	202	56	12	5	3	3	1	1	1747

**Study status as of April 30, 2020*

**Table 6 Combined Cohort. Route and Chemotherapy Specific Percentile Dose Distributions
SJLIFE Campus Visit Participants (N=5229)***

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
3F8 (Murine IgG3)	Intravenous	mg	1	2380	2380	2380	2380	2380
5-Azacytidine	Intravenous	mg	31	600	600	600	1050	1800
6-Azauridine	Intravenous	mg	19	14943	90000	144231	163362	221391
9-Aminocamptothecin	Intravenous	mg	1	65	65	65	65	65
Aldesleukin (Interleukin-2)	Intramuscular	million	1	6	6	6	6	6
	Intravenous	million	18	24	49	60	61	216
	Oral	million	1	6	6	6	6	6
	Subcutaneous	million	14	5	6	7	18	67
Alemtuzumab	Intravenous	mg	2	41	41	44	46	46
	Subcutaneous	mg	2	46	46	98	150	150
Alpha Interferon	Intramuscular	million	1	1884	1884	1884	1884	1884
	Subcutaneous	million	10	82	290	849	1031	20500
Amifostine	Intravenous	mg	82	3535	4656	4762	4845	4920
	Subcutaneous	mg	3	4577	4577	4691	4804	4804
Amikacin	-9999		39	.	.	.	.	.
	IV	mg	551	2228	3823	8075	14718	26247
	PO	mg	1	3328	3328	3328	3328	3328
Amsacrine	Intravenous	mg	22	374	374	375	382	1301
Anastrozole (Arimidex)	Oral	mg	6	19	19	19	19	19
Arsenic Trioxide (Trisenox)	Intravenous	mg	9	86	162	229	291	327
Bendamustine (Treanda)	Intravenous	mg	3	238	238	590	1087	1087
Bevacizumab (Avastin)	Intravenous	mg	28	1091	1738	3344	4399	6395
Bleomycin	Intravenous	units	288	21	30	40	69	98
Bortezomib	Intravenous	mg	4	4	4	11	19	19
Brentuximab vedotin	Intravenous	mg	5	67	71	284	380	1554
Busulfan	Intravenous	mg	39	185	309	443	551	620
	Oral	mg	27	331	369	440	552	694
Capecitabine (Xeloda)	Oral	mg	9	1875	37917	43165	55825	70986
Carboplatin	Intraocular	mg	15	83	95	109	136	146
	Intravenous	mg	492	954	1600	2785	3939	5074
	Subtenon	mg	2	75	75	89	103	103
Carmustine	Intravenous	mg	35	101	203	297	300	303

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
Cetuximab (Erbix)	Intravenous	mg	2	3854	3854	3854	3854	3854
Chlorambucil (Leukeran)	Intravenous	mg	2	59	59	65	71	71
Cisplatin	Intraarterial	mg	1	43	43	43	43	43
	Intravenous	mg	560	199	291	343	452	598
Cladribine	Intravenous	mg	95	43	45	45	75	100
Clofarabine	Intravenous	mg	30	197	204	260	402	683
Cloretazine (NTO-1152)	Intravenous	mg	1	456	456	456	456	456
Cyclophosphamide	-9999		1	.	.	.	.	.
	Intravenous	mg	2638	1050	3167	5887	10018	15548
	Oral	mg	319	1922	4200	6136	10993	17424
	Subcutaneous	mg	1	100	100	100	100	100
Cyclosporine	Intravenous	mg	2	136	136	413	690	690
	Oral	mg	5	8618	8618	96444	269674	269674
Cytarabine	Intramuscular	mg	1	6100	6100	6100	6100	6100
	Intraommaya	mg	10	153	228	381	663	756
	Intrathecal	mg	1493	119	290	503	741	1019
	Intravenous	mg	1646	606	1203	3684	8930	10903
	Subcutaneous	mg	68	600	1165	3632	8359	10237
Cytarabine Liposomal	Intrathecal	mg	2	77	77	104	131	131
Cytarabine: High-Dose	Intravenous	mg	545	6000	8000	13303	24000	40237
DMP 840	Intravenous	mg	1	173	173	173	173	173
Dacarbazine (DTIC)	Intravenous	mg	115	1366	1509	1967	2500	5305
Dactinomycin	Intravenous	mg	631	3	5	8	12	16
Dasatinib (Sprycel)	Oral	mg	5	9200	11760	21756	38267	47343
Daunorubicin (Daunomycin)	Intravenous	mg	1381	49	50	90	107	201
Dexamethasone (Decadron)	Intrathecal	mg	4	2	7	17	26	30
	Intravenous	mg	67	40	152	317	472	672
	Oral	mg	727	.	.	.	.	.
Dinutuximab (ch14.18)	Intravenous	mg	11	498	502	513	517	517
Docetaxel (Taxotere)	Intravenous	mg	24	208	237	353	438	554
Doxorubicin (Adriamycin)	Intraarterial	mg	1	7	7	7	7	7
	Intravenous	mg	2050	63	123	178	267	375
Epirubicin	Intravenous	mg	8	83	270	408	459	485
Erlotinib	Oral	mg	19	1909	5385	6667	34043	88038
Erwinia Asparaginase	Intramuscular	units	192	20000	50000	111186	359981	754359

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
	Intravenous	units	29	19091	30000	40000	74324	394340
Etopophos	Intravenous	mg	53	503	800	973	1600	2920
Etoposide	Intravenous	mg	1564	401	921	2025	7180	12902
	Oral	mg	59	575	950	1615	2856	3228
Everolimus	Oral	mg	1	925	925	925	925	925
Exemestane (Aromasin)	Oral	mg	3	.	.	.	.	.
Fludarabine	Intravenous	mg	52	60	86	133	199	201
Fluorouracil (5FU)	Intraocular	mg	2	29	29	53	77	77
	Intravenous	mg	72	2405	3665	11968	14704	17768
Gamma Interferon	Subcutaneous	mcg	2	253	253	266	279	279
Gefitinib (Iressa, ZD1839)	Oral	mg	8	2308	2721	3584	9175	38530
Gemcitabine	Intravenous	mg	21	1982	4758	6028	8160	15592
Gemtuzumab	Intravenous	mg	21	2	3	3	4	6
Gentamicin	-9999		48	.	.	.	.	.
	IM	mg	4	127	146	605	1046	1048
	IV	mg	477	143	480	1105	2439	4546
Hu14.18K322A (humanized monoclonal anti-GD2 antibody)	Intravenous	mg	2	96	96	209	323	323
Hydrocortisone	Intraommaya	mg	8	69	97	154	278	663
	Intrathecal	mg	1386	86	197	336	494	669
	Intravenous	mg	13	45	140	351	988	1098
	Oral		1	.	.	.	.	.
Hydroxyurea	Oral	mg	36	6667	12766	44865	100338	159574
Idarubicin	Intravenous	mg	47	10	11	20	36	54
Ifosfamide	Intravenous	mg	415	12145	23831	41665	60591	72358
Imatinib (Gleevec)	Oral	mg	16	2791	18592	75469	83495	138478
Interferon	Subcutaneous	million	4	70	288	540	784	992
Interferon Alpha-2a	Intramuscular	million	1	420	420	420	420	420
	Intravenous	million	2	403	403	878	1352	1352
	Subcutaneous	million	9	14	179	236	733	942
Interferon Alpha-2b	Intramuscular	million	2	419	419	26321	52224	52224
	Intravenous	million	18	272	380	399	405	1898
	Subcutaneous	million	11	735	893	1209	1428	1735
Interleukin-3	Subcutaneous	units	1	6248	6248	6248	6248	6248
Irinotecan (Camptosar)	Intravenous	mg	31	302	400	781	1547	2547

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
Isotretinoin (Accutane)	Oral	mg	40	7304	8794	12923	14467	22985
Kanamycin	-9999		46	.	.	.	.	.
	IM	mg	2	600	600	1690	2781	2781
	IV	mg	41	1200	2594	3387	4081	5304
L-Asparaginase	Intramuscular	units	1126	30112	59737	100287	152895	312873
	Intravenous	units	340	19559	20000	39503	40571	79211
	Subcutaneous	units	1	238421	238421	238421	238421	238421
Lapatinib	Oral	mg	2	391	391	114394	228397	228397
Letrozole (Femara)	Oral		2	.	.	.	.	.
Lomustine	Oral	mg	21	110	348	453	725	789
Mafosfamide	Intraommaya	mg	5	84	155	163	204	286
	Intrathecal	mg	9	56	124	229	246	434
	Intravenous	mg	1	248	248	248	248	248
Mechlorethamine (Nitrogen Mustard)	Intravenous	mg	130	12	18	18	19	36
	Topical	mg	1	.	.	.	.	.
Melphalan	Intravenous	mg	102	114	126	140	179	182
Mercaptopurine	Intravenous	mg	195	998	1000	1000	2954	4507
	Oral	mg	1681	4509	12101	22233	43842	59121
Methotrexate	-9999		1	.	.	.	.	.
	Intramuscular	mg	344	406	900	1213	2329	3805
	Intraommaya	mg	13	13	51	73	94	145
	Intrathecal	mg	1909	52	82	158	237	331
	Intravenous	mg	1302	126	667	2155	3261	4095
	Oral	mg	524	150	213	1654	2624	3900
Methotrexate: High-Dose	Intravenous	mg	1442	4000	8568	16189	21453	39124
Methylprednisolone	Intravenous	mg	60	19	40	81	434	996
	Oral	mg	9	17	20	84	541	4174
Mitomycin (Mutamycin)	Intravenous	mg	2	19	19	24	30	30
Mitotane	Oral	mg	2	709804	709804	1513984	2318164	2318164
Mitoxantrone	Intravenous	mg	136	20	25	35	50	68
Muromonab-CD3 (OKT3)	Intravenous	mg	3	42	42	57	74	74
Nab-paclitaxel (Abraxane)	Intravenous	mg	1	1554	1554	1554	1554	1554
Nelarabine	Intravenous	mg	1	2000	2000	2000	2000	2000
Neuraminidase	Intravenous	units	1	6410	6410	6410	6410	6410
Nilotinib	Oral	mg	1	13034	13034	13034	13034	13034

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
Nivolumab (Opdivo)	Intravenous	mg	2	267	267	452	636	636
Octreotide	Intramuscular	mcg	1	85737	85737	85737	85737	85737
Olaratumab (Lartruvo)	Intravenous	mg	1	7554	7554	7554	7554	7554
Oxaliplatin	Intravenous	mg	12	214	350	738	976	1424
Paclitaxel	Intravenous	mg	16	172	686	957	990	1588
Panitumumab (Vectibix)	Intravenous		1	.	.	.	.	.
Pazopanib (Votrient)	Intravenous	mg	1	18647	18647	18647	18647	18647
	Oral		1	.	.	.	.	.
Peg-Asparaginase	Intramuscular	units	144	2515	5020	10199	17699	39615
	Intravenous	units	137	7482	13500	18000	42633	55938
Peginterferon Alpha-2b	Subcutaneous	mcg	11	445	985	1445	1569	6286
Pembrolizumab	Intravenous	mg	1	367	367	367	367	367
Pemetrexed	Intravenous	mg	2	.	.	.	.	.
Pentostatin	Intravenous	mg	1	2	2	2	2	2
Prednisolone	Intravenous	mg	7	22	55	92	238	375
	Oral	mg	68	.	.	.	.	.
Prednisone	Oral	mg	2081	.	.	.	.	.
Procarbazine	Oral	mg	249	2400	3462	4018	5476	7947
Rituximab	Intravenous	mg	31	372	375	564	1142	2237
Robatumumab (SCH717454)	Intravenous		1	.	.	.	.	.
Sirolimus	Oral	mg	2	54	54	270	487	487
Sorafenib	Oral	mg	5	3958	9412	35366	58000	77306
Streptomycin	-9999		47	.	.	.	.	.
	IV	mg	7	960	960	2552	4145	4145
Sulindac	Oral	mg	2	11827	11827	26574	41321	41321
Tamoxifen	Oral	mg	21	204	1747	9564	10440	14104
Temozolomide	Intravenous		1	.	.	.	.	.
	Oral	mg	35	2422	4456	6308	10408	14593
Temsirolimus	Intravenous	mg	3	451	451	543	591	591
Teniposide	Intravenous	mg	565	600	1355	3117	5332	6568
Thalidomide	Oral	mg	1	27539	27539	27539	27539	27539
Thioguanine	Intravenous	mg	15	528	636	794	846	1731
	Oral	mg	215	431	653	800	875	2229
Thiotepa	Intravenous	mg	87	200	245	297	402	900
Tipifarnib (Zarnestra)	Oral	mg	1	14483	14483	14483	14483	14483

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
Tobramycin	-9999		11	.	.	.	.	.
	IM	mg	1	3	3	3	3	3
	IV	mg	818	360	659	1208	2783	5082
	Inhalation	mg	1	207	207	207	207	207
	PO		1	.	.	.	.	.
Topotecan	Intraommay	mg	1	7	7	7	7	7
	Intrathecal	mg	2	1	1	1	1	1
	Intravenous	mg	112	12	26	41	68	82
	Oral	mg	31	19	23	26	51	120
Trastuzumab	Intravenous	mg	5	2653	2653	3160	3667	3667
Tretinoin (Retin A)	Oral	mg	28	960	1902	4160	10951	16208
Trimetrexate	Intravenous	mg	1	944	944	944	944	944
Valproic acid (Depakote)	Intravenous	mg	1	3879	3879	3879	3879	3879
	Oral	mg	3	2500	2500	7029	7633	7633
Vinblastine	Intravenous	mg	473	24	36	39	50	87
Vincristine	Intravenous	mg	3428	6	8	22	53	64
Vinorelbine	Intravenous	mg	16	30	71	111	150	153
Vismodegib (Erivedge)	Oral		1	.	.	.	.	.
Vorinostat (Zolinza)	Oral	mg	3	900	900	5040	6250	6250
XomaZyme	Intravenous	mg	3	41	41	67	69	69

**Study status as of April 30, 2020*

**Table 6 Original Cohort. Route and Chemotherapy Specific Percentile Dose Distributions
SJLIFE Campus Visit Participants (N=3482)***

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
5-Azacytidine	Intravenous	mg	31	600	600	600	1050	1800
6-Azauridine	Intravenous	mg	19	14943	90000	144231	163362	221391
9-Aminocamptothecin	Intravenous	mg	1	65	65	65	65	65
Aldesleukin (Interleukin-2)	Intravenous	million units	5	49	60	60	130	216
	Subcutaneous	million units	2	67	67	78	90	90
Alpha Interferon	Intramuscular	million units	1	1884	1884	1884	1884	1884
	Subcutaneous	million units	10	82	290	849	1031	20500
Amifostine	Intravenous	mg	10	4725	4748	4805	4858	4876
Amikacin	-9999		7	.	.	.	.	.
	IV	mg	536	2228	4030	8200	15566	27432
	PO	mg	1	3328	3328	3328	3328	3328
Amsacrine	Intravenous	mg	22	374	374	375	382	1301
Anastrozole (Arimidex)	Oral	mg	6	19	19	19	19	19
Arsenic Trioxide (Trisenox)	Intravenous	mg	5	183	229	291	318	327
Bendamustine (Treanda)	Intravenous	mg	1	1087	1087	1087	1087	1087
Bevacizumab (Avastin)	Intravenous	mg	6	4305	4305	6801	9298	9298
Bleomycin	Intravenous	units	178	26	39	59	79	119
Brentuximab vedotin	Intravenous	mg	1	380	380	380	380	380
Busulfan	Intravenous	mg	12	367	412	513	597	620
	Oral	mg	26	331	369	435	526	575
Capecitabine (Xeloda)	Oral	mg	9	1875	37917	43165	55825	70986
Carboplatin	Intravenous	mg	200	975	1642	2783	4013	5554
Carmustine	Intravenous	mg	17	97	103	203	300	465
Cetuximab (Erbix)	Intravenous	mg	2	3854	3854	3854	3854	3854
Chlorambucil (Leukeran)	Intravenous	mg	2	59	59	65	71	71
Cisplatin	Intraarterial	mg	1	43	43	43	43	43
	Intravenous	mg	299	182	285	397	469	676
Cladribine	Intravenous	mg	54	44	45	45	88	91
Cyclophosphamide	-9999		1	.	.	.	.	.
	Intravenous	mg	1757	1841	3590	6966	10162	15246
	Oral	mg	291	3442	4257	6636	12064	18052
	Subcutaneous	mg	1	100	100	100	100	100

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
Cyclosporine	Oral	mg	3	269674	269674	269674	269674	269674
Cytarabine	Intramuscular	mg	1	6100	6100	6100	6100	6100
	Intraommaya	mg	7	99	208	275	663	752
	Intrathecal	mg	936	166	323	500	720	972
	Intravenous	mg	1093	919	1529	4929	9943	11172
	Subcutaneous	mg	65	750	1420	4412	8434	10237
Cytarabine Liposomal	Intrathecal	mg	1	77	77	77	77	77
Cytarabine: High-Dose	Intravenous	mg	247	4894	8000	17561	21006	29925
DMP 840	Intravenous	mg	1	173	173	173	173	173
Dacarbazine (DTIC)	Intravenous	mg	109	1366	1516	1969	2500	6215
Dactinomycin	Intravenous	mg	491	3	5	8	12	16
Dasatinib (Sprycel)	Oral	mg	1	.	.	.	.	.
Daunorubicin (Daunomycin)	Intravenous	mg	886	49	50	100	106	188
Dexamethasone (Decadron)	Intrathecal	mg	3	2	2	22	30	30
	Intravenous	mg	42	50	164	322	507	781
	Oral	mg	329	.	.	.	.	.
Docetaxel (Taxotere)	Intravenous	mg	20	222	243	396	441	631
Doxorubicin (Adriamycin)	Intraarterial	mg	1	7	7	7	7	7
	Intravenous	mg	1282	112	152	195	313	382
Epirubicin	Intravenous	mg	5	83	270	399	452	485
Erwinia Asparaginase	Intramuscular	units	133	20000	40114	61208	137671	589273
	Intravenous	units	20	14631	25000	31223	44937	50465
Etopophos	Intravenous	mg	5	800	1400	1412	1600	1600
Etoposide	Intravenous	mg	1024	791	1213	3480	9736	14280
	Oral	mg	31	539	700	1100	1406	2628
Exemestane (Aromasin)	Oral	mg	3	.	.	.	.	.
Fludarabine	Intravenous	mg	17	59	60	61	178	235
Fluorouracil (5FU)	Intravenous	mg	56	2417	3768	12068	15678	18096
Gefitinib (Iressa, ZD1839)	Oral	mg	1	14000	14000	14000	14000	14000
Gemcitabine	Intravenous	mg	11	1000	2000	7125	8182	34037
Gentamicin	-9999		13	.	.	.	.	.
	IM	mg	4	127	146	605	1046	1048
	IV	mg	436	325	678	1263	2613	4959
Hydrocortisone	Intraommaya	mg	5	69	95	99	270	663
	Intrathecal	mg	870	103	213	332	480	638

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
	Intravenous	mg	2	379	379	2000	3621	3621
	Oral		1	.	.	.	.	.
Hydroxyurea	Oral	mg	30	8383	14493	58214	100338	159574
Idarubicin	Intravenous	mg	33	10	11	20	35	38
Ifosfamide	Intravenous	mg	270	15840	25005	41638	58833	71966
Imatinib (Gleevec)	Oral	mg	7	2581	2791	75469	80687	83495
Interferon	Subcutaneous	million units	4	70	288	540	784	992
Interferon Alpha-2a	Intramuscular	million units	1	420	420	420	420	420
	Intravenous	million units	1	1352	1352	1352	1352	1352
	Subcutaneous	million units	9	14	179	236	733	942
Interferon Alpha-2b	Intramuscular	million units	1	419	419	419	419	419
	Intravenous	million units	3	263	263	382	399	399
	Subcutaneous	million units	8	121	955	1225	1384	1735
Interleukin-3	Subcutaneous	units	1	6248	6248	6248	6248	6248
Irinotecan (Camptosar)	Intravenous	mg	11	397	825	1139	1634	2547
Isotretinoin (Accutane)	Oral	mg	2	446	446	6768	13091	13091
Kanamycin	-9999		11	.	.	.	.	.
	IM	mg	2	600	600	1690	2781	2781
	IV	mg	41	1200	2594	3387	4081	5304
L-Asparaginase	Intramuscular	units	841	44722	59737	90390	133516	254337
	Intravenous	units	320	19688	20000	39506	40476	77895
Letrozole (Femara)	Oral		2	.	.	.	.	.
Lomustine	Oral	mg	15	222	348	446	630	754
Mechlorethamine (Nitrogen Mustard)	Intravenous	mg	56	12	18	18	36	72
	Topical	mg	1	.	.	.	.	.
Melphalan	Intravenous	mg	20	89	120	140	140	141
Mercaptopurine	Intravenous	mg	185	1000	1000	1000	3000	4734
	Oral	mg	1266	4772	13015	18026	42368	54755
Methotrexate	-9999		1	.	.	.	.	.
	Intramuscular	mg	327	406	905	1214	2405	3838
	Intraommaya	mg	10	11	35	67	88	122
	Intrathecal	mg	1367	55	79	154	226	319
	Intravenous	mg	907	121	332	1622	2752	3834
	Oral	mg	456	178	400	1751	2722	3948
Methotrexate: High-Dose	Intravenous	mg	955	4000	4183	16118	22125	45896

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
Methylprednisolone	Intravenous	mg	22	25	74	142	610	3753
	Oral	mg	1	4174	4174	4174	4174	4174
Mitomycin (Mutamycin)	Intravenous	mg	2	19	19	24	30	30
Mitotane	Oral	mg	1	709804	709804	709804	709804	709804
Mitoxantrone	Intravenous	mg	38	30	36	50	51	80
Nab-paclitaxel (Abraxane)	Intravenous	mg	1	1554	1554	1554	1554	1554
Nelarabine	Intravenous	mg	1	2000	2000	2000	2000	2000
Neuraminidase	Intravenous	units	1	6410	6410	6410	6410	6410
Nivolumab (Opdivo)	Intravenous	mg	2	267	267	452	636	636
Octreotide	Intramuscular	mcg	1	85737	85737	85737	85737	85737
Olaratumab (Lartruvo)	Intravenous	mg	1	7554	7554	7554	7554	7554
Oxaliplatin	Intravenous	mg	9	168	350	735	976	1000
Paclitaxel	Intravenous	mg	15	172	695	958	990	1588
Panitumumab (Vectibix)	Intravenous		1	.	.	.	.	.
Pazopanib (Votrient)	Intravenous	mg	1	18647	18647	18647	18647	18647
	Oral		1	.	.	.	.	.
Peg-Asparaginase	Intramuscular	units	43	2542	5000	10333	23071	38250
	Intravenous	units	1	20051	20051	20051	20051	20051
Pemetrexed	Intravenous	mg	2	.	.	.	.	.
Prednisolone	Intravenous	mg	4	55	67	159	307	375
	Oral	mg	9	.	.	.	.	.
Prednisone	Oral	mg	1579	.	.	.	.	.
Procarbazine	Oral	mg	240	2480	3527	4027	5574	7990
Rituximab	Intravenous	mg	12	373	750	912	2237	2258
Streptomycin	-9999		11	.	.	.	.	.
	IV	mg	6	4145	4145	4145	4145	4145
Sulindac	Oral	mg	1	41321	41321	41321	41321	41321
Tamoxifen	Oral	mg	16	204	3673	9623	10440	18014
Temozolomide	Oral	mg	11	3163	5615	6300	13730	47291
Teniposide	Intravenous	mg	552	600	1358	3197	5357	6602
Thioguanine	Intravenous	mg	6	63	681	835	1731	1739
	Oral	mg	33	599	875	1956	9488	15626
Thiotepa	Intravenous	mg	26	50	273	349	614	900
Tobramycin	-9999		11	.	.	.	.	.
	IV	mg	398	480	833	1630	3343	5112

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
	Inhalation	mg	1	207	207	207	207	207
	PO		1	.	.	.	.	.
Topotecan	Intrathecal	mg	2	1	1	1	1	1
	Intravenous	mg	37	10	12	27	45	64
	Oral	mg	1	48	48	48	48	48
Trastuzumab	Intravenous	mg	4	2653	2653	3160	3667	3667
Tretinoin (Retin A)	Oral	mg	17	583	1645	2773	8144	16208
Trimetrexate	Intravenous	mg	1	944	944	944	944	944
Vinblastine	Intravenous	mg	334	25	36	46	51	77
Vincristine	Intravenous	mg	2370	6	9	25	52	61
Vinorelbine	Intravenous	mg	4	25	28	40	100	150
Vismodegib (Erivedge)	Oral		1	.	.	.	.	.
XomaZyme	Intravenous	mg	3	41	41	67	69	69

**Study status as of April 30, 2020*

**Table 6 Expansion Cohort. Route and Chemotherapy Specific Percentile Dose Distributions
SJLIFE Campus Visit Participants (N=1747)***

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
3F8 (Murine IgG3)	Intravenous	mg	1	2380	2380	2380	2380	2380
Aldesleukin (Interleukin-2)	Intramuscular	million	1	6	6	6	6	6
	Intravenous	million	13	24	49	58	61	64
	Oral	million	1	6	6	6	6	6
Alemtuzumab	Subcutaneous	million	12	5	6	6	13	18
	Intravenous	mg	2	41	41	44	46	46
Amifostine	Subcutaneous	mg	2	46	46	98	150	150
	Intravenous	mg	72	3534	4641	4756	4842	4931
Amikacin	Subcutaneous	mg	3	4577	4577	4691	4804	4804
	-9999		32	.	.	.	.	.
Arsenic Trioxide (Trisenox)	IV	mg	15	1742	2600	3500	7000	10257
	Intravenous	mg	4	86	111	150	212	262
Bendamustine (Treanda)	Intravenous	mg	2	238	238	414	590	590
Bevacizumab (Avastin)	Intravenous	mg	22	1091	1388	3026	4067	4795
Bleomycin	Intravenous	units	110	20	29	30	31	61
Bortezomib	Intravenous	mg	4	4	4	11	19	19
Brentuximab vedotin	Intravenous	mg	4	67	69	177	919	1554
Busulfan	Intravenous	mg	27	181	276	380	550	613
	Oral	mg	1	758	758	758	758	758
Carboplatin	Intraocular	mg	15	83	95	109	136	146
	Intravenous	mg	292	876	1526	2785	3766	4970
	Subtenon	mg	2	75	75	89	103	103
Carmustine	Intravenous	mg	18	272	277	299	300	302
Cisplatin	Intravenous	mg	261	222	291	304	440	560
Cladribine	Intravenous	mg	41	31	45	45	54	147
Clofarabine	Intravenous	mg	30	197	204	260	402	683
Cloretazine (NTO-1152)	Intravenous	mg	1	456	456	456	456	456
Cyclophosphamide	Intravenous	mg	881	1000	2083	4462	8981	15744
	Oral	mg	28	1050	1561	1867	1961	6133
Cyclosporine	Intravenous	mg	2	136	136	413	690	690
	Oral	mg	2	8618	8618	52531	96444	96444
Cytarabine	Intraommaya	mg	3	407	407	421	759	759

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
	Intrathecal	mg	557	90	200	506	800	1138
	Intravenous	mg	553	591	610	1780	4119	5810
	Subcutaneous	mg	3	600	600	1009	1066	1066
Cytarabine Liposomal	Intrathecal	mg	1	131	131	131	131	131
Cytarabine: High-Dose	Intravenous	mg	298	6061	8000	8281	25455	48000
Dacarbazine (DTIC)	Intravenous	mg	6	754	1509	1509	1573	3003
Dactinomycin	Intravenous	mg	140	4	5	7	10	15
Dasatinib (Sprycel)	Oral	mg	4	9200	11760	21756	38267	47343
Daunorubicin (Daunomycin)	Intravenous	mg	495	47	49	50	120	280
Dexamethasone (Decadron)	Intrathecal	mg	1	12	12	12	12	12
	Intravenous	mg	25	20	91	259	436	461
	Oral	mg	398	.	.	.	.	.
Dinutuximab (ch14.18)	Intravenous	mg	11	498	502	513	517	517
Docetaxel (Taxotere)	Intravenous	mg	4	74	74	309	409	409
Doxorubicin (Adriamycin)	Intravenous	mg	768	43	75	146	182	351
Epirubicin	Intravenous	mg	3	408	408	433	459	459
Erlotinib	Oral	mg	19	1909	5385	6667	34043	88038
Erwinia Asparaginase	Intramuscular	units	59	58065	174930	284227	629300	858417
	Intravenous	units	9	23885	74324	182000	394340	2439000
Etopophos	Intravenous	mg	48	498	766	964	1529	3074
Etoposide	Intravenous	mg	540	360	511	1100	2123	4050
	Oral	mg	28	764	1628	2591	3150	3290
Everolimus	Oral	mg	1	925	925	925	925	925
Fludarabine	Intravenous	mg	35	104	125	148	200	201
Fluorouracil (5FU)	Intraocular	mg	2	29	29	53	77	77
	Intravenous	mg	16	661	2891	8091	12156	12306
Gamma Interferon	Subcutaneous	mcg	2	253	253	266	279	279
Gefitinib (Iressa, ZD1839)	Oral	mg	7	2308	2500	3182	4350	38530
Gemcitabine	Intravenous	mg	10	4758	4955	5493	7214	11074
Gemtuzumab	Intravenous	mg	21	2	3	3	4	6
Gentamicin	-9999		35	.	.	.	.	.
	IV	mg	41	41	131	269	647	1294
Hu14.18K322A (humanized monoclonal anti-GD2 antibody)	Intravenous	mg	2	96	96	209	323	323
Hydrocortisone	Intraommaya	mg	3	126	126	182	285	285
	Intrathecal	mg	516	74	166	343	537	726

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
	Intravenous	mg	11	45	74	289	986	1045
Hydroxyurea	Oral	mg	6	357	2663	12766	14596	544762
Idarubicin	Intravenous	mg	14	10	11	30	50	54
Ifosfamide	Intravenous	mg	145	11500	18651	42970	63114	72742
Imatinib (Gleevec)	Oral	mg	9	9634	19078	62717	126608	261188
Interferon Alpha-2a	Intravenous	million	1	403	403	403	403	403
Interferon Alpha-2b	Intramuscular	million	1	52224	52224	52224	52224	52224
	Intravenous	million	15	327	380	400	1752	1898
	Subcutaneous	million	3	893	893	971	1740	1740
Irinotecan (Camptosar)	Intravenous	mg	20	299	394	517	1473	2272
Isotretinoin (Accutane)	Oral	mg	38	7508	9164	12923	14483	22985
Kanamycin	-9999		35	.	.	.	.	.
L-Asparaginase	Intramuscular	units	285	11897	60317	122000	251486	524943
	Intravenous	units	20	11748	12000	33729	111917	253618
	Subcutaneous	units	1	238421	238421	238421	238421	238421
Lapatinib	Oral	mg	2	391	391	114394	228397	228397
Lomustine	Oral	mg	6	110	321	630	759	789
Mafofosfamide	Intraommaya	mg	5	84	155	163	204	286
	Intrathecal	mg	9	56	124	229	246	434
	Intravenous	mg	1	248	248	248	248	248
Mechlorethamine (Nitrogen Mustard)	Intravenous	mg	74	12	18	18	18	19
Melphalan	Intravenous	mg	82	118	127	140	180	182
Mercaptopurine	Intravenous	mg	10	397	998	1000	1000	1000
	Oral	mg	415	4325	8972	31821	44536	65464
Methotrexate	Intramuscular	mg	17	362	620	1025	1500	2574
	Intraommaya	mg	3	51	51	114	145	145
	Intrathecal	mg	542	43	86	180	271	380
	Intravenous	mg	395	609	1775	2930	3772	4744
	Oral	mg	68	39	123	990	2120	2798
Methotrexate: High-Dose	Intravenous	mg	487	8983	10552	16323	20045	27014
Methylprednisolone	Intravenous	mg	38	13	35	59	167	678
	Oral	mg	8	17	20	39	129	541
Mitotane	Oral	mg	1	2318164	2318164	2318164	2318164	2318164
Mitoxantrone	Intravenous	mg	98	20	23	31	48	51
Muromonab-CD3 (OKT3)	Intravenous	mg	3	42	42	57	74	74

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
Nilotinib	Oral	mg	1	13034	13034	13034	13034	13034
Oxaliplatin	Intravenous	mg	3	260	260	774	1848	1848
Paclitaxel	Intravenous	mg	1	177	177	177	177	177
Peg-Asparaginase	Intramuscular	units	101	2500	5040	10167	17474	39615
	Intravenous	units	136	7482	13487	17996	42894	55938
Peginterferon Alpha-2b	Subcutaneous	mcg	11	445	985	1445	1569	6286
Pembrolizumab	Intravenous	mg	1	367	367	367	367	367
Pentostatin	Intravenous	mg	1	2	2	2	2	2
Prednisolone	Intravenous	mg	3	22	22	92	159	159
	Oral	mg	59	.	.	.	.	.
Prednisone	Oral	mg	502	.	.	.	.	.
Procarbazine	Oral	mg	9	247	1273	1471	2523	3929
Rituximab	Intravenous	mg	19	372	375	375	1122	1484
Robatumumab (SCH717454)	Intravenous		1	.	.	.	.	.
Sirolimus	Oral	mg	2	54	54	270	487	487
Sorafenib	Oral	mg	5	3958	9412	35366	58000	77306
Streptomycin	-9999		36	.	.	.	.	.
	IV	mg	1	960	960	960	960	960
Sulindac	Oral	mg	1	11827	11827	11827	11827	11827
Tamoxifen	Oral	mg	5	84	203	4942	11243	12923
Temozolomide	Intravenous		1	.	.	.	.	.
	Oral	mg	24	2033	3022	6317	8830	13082
Temsirolimus	Intravenous	mg	3	451	451	543	591	591
Teniposide	Intravenous	mg	13	164	165	330	2389	3080
Thalidomide	Oral	mg	1	27539	27539	27539	27539	27539
Thioguanine	Intravenous	mg	9	528	636	764	842	894
	Oral	mg	182	414	647	784	844	921
Thiotepa	Intravenous	mg	61	219	245	283	366	533
Tipifarnib (Zarnestra)	Oral	mg	1	14483	14483	14483	14483	14483
Tobramycin	IM	mg	1	3	3	3	3	3
	IV	mg	420	265	531	1020	2085	4902
Topotecan	Intraommaya	mg	1	7	7	7	7	7
	Intravenous	mg	75	21	33	54	73	82
	Oral	mg	30	18	23	26	51	123
Trastuzumab	Intravenous		1	.	.	.	.	.

Cumulative Dose (when known): Percentiles								
Chemotherapy Agent	Route	Units/m ²	N	10th	25th	50th	75th	90th
Tretinoin (Retin A)	Oral	mg	11	3788	4160	9228	13616	17908
Valproic acid (Depakote)	Intravenous	mg	1	3879	3879	3879	3879	3879
	Oral	mg	3	2500	2500	7029	7633	7633
Vinblastine	Intravenous	mg	139	24	35	37	49	114
Vincristine	Intravenous	mg	1058	6	8	16	56	67
Vinorelbine	Intravenous	mg	12	99	99	125	152	153
Vorinostat (Zolinza)	Oral	mg	3	900	900	5040	6250	6250

**Study status as of April 30, 2020*

**Table 7 Combined Cohort. Radiation Exposure among SJLIFE Campus Visit Participants
by Primary Diagnosis and Treatment Field (N=5229)***

Primary Diagnosis	Radiation Treatment Field - Potential Impact**						
	Total N	None N (%)	Any N (%)	Brain/Cranium N (%)	Chest N (%)	Abdomen N (%)	Pelvis N (%)
Acute lymphoblastic leukemia	1485	822 (55.4)	663 (44.6)	644 (43.4)	180 (12.1)	168 (11.3)	167 (11.2)
Acute myeloid leukemia	243	153 (63.0)	90 (37.0)	88 (36.2)	78 (32.1)	77 (31.7)	77 (31.7)
Other leukemia	43	9 (20.9)	34 (79.1)	33 (76.7)	34 (79.1)	34 (79.1)	33 (76.7)
Other hematologic malignancy	42	35 (83.3)	7 (16.7)	7 (16.7)	1 (2.4)	1 (2.4)	1 (2.4)
CNS tumor	765	236 (30.8)	529 (69.2)	525 (68.6)	253 (33.1)	253 (33.1)	253 (33.1)
Ewing sarcoma family of tumors	133	28 (21.1)	105 (78.9)	15 (11.3)	35 (26.3)	16 (12.0)	40 (30.1)
Osteosarcoma	177	164 (92.7)	13 (7.3)	3 (1.7)	5 (2.8)	3 (1.7)	6 (3.4)
Germ cell tumor	105	87 (82.9)	18 (17.1)	1 (1.0)	10 (9.5)	9 (8.6)	15 (14.3)
Hepatoblastoma	37	35 (94.6)	2 (5.4)	0 (0.0)	2 (5.4)	2 (5.4)	0 (0.0)
Hodgkin lymphoma	522	32 (6.1)	490 (93.9)	27 (5.2)	461 (88.3)	257 (49.2)	143 (27.4)
Non-Hodgkin lymphoma	318	217 (68.2)	101 (31.8)	56 (17.6)	50 (15.7)	32 (10.1)	34 (10.7)
Melanoma	46	43 (93.5)	3 (6.5)	1 (2.2)	1 (2.2)	0 (0.0)	0 (0.0)
Neuroblastoma	249	169 (67.9)	80 (32.1)	8 (3.2)	73 (29.3)	61 (24.5)	40 (16.1)
Retinoblastoma	308	210 (68.2)	98 (31.8)	97 (31.5)	3 (1.0)	1 (0.3)	2 (0.6)
RMS	170	34 (20.0)	136 (80.0)	68 (40.0)	29 (17.1)	22 (12.9)	53 (31.2)
Non-RMS	146	63 (43.2)	83 (56.8)	14 (9.6)	26 (17.8)	13 (8.9)	15 (10.3)
Wilms tumor	312	121 (38.8)	191 (61.2)	1 (0.3)	191 (61.2)	185 (59.3)	166 (53.2)
Carcinomas	72	31 (43.1)	41 (56.9)	38 (52.8)	5 (6.9)	1 (1.4)	2 (2.8)
Other malignancy	38	21 (55.3)	17 (44.7)	5 (13.2)	7 (18.4)	5 (13.2)	8 (21.1)
Other neoplasm	18	12 (66.7)	6 (33.3)	1 (5.6)	4 (22.2)	2 (11.1)	2 (11.1)
All Diagnoses	5229	2522	2707	1632	1448	1142	1057

**Study status as of April 30, 2020 **Fields are not mutually exclusive*

**Table 7 Original Cohort. Radiation Exposure among SJLIFE Campus Visit Participants
by Primary Diagnosis and Treatment Field (N=3482)***

Primary Diagnosis	Radiation Treatment Field - Potential Impact**						
	Total N	None N (%)	Any N (%)	Brain/Cranium N (%)	Chest N (%)	Abdomen N (%)	Pelvis N (%)
Acute lymphoblastic leukemia	1107	483 (43.6)	624 (56.4)	608 (54.9)	150 (13.6)	138 (12.5)	137 (12.4)
Acute myeloid leukemia	130	73 (56.2)	57 (43.8)	57 (43.8)	46 (35.4)	46 (35.4)	46 (35.4)
Other leukemia	29	3 (10.3)	26 (89.7)	25 (86.2)	26 (89.7)	26 (89.7)	25 (86.2)
Other hematologic malignancy	21	17 (81.0)	4 (19.0)	4 (19.0)	0 (0.0)	0 (0.0)	0 (0.0)
CNS tumor	390	125 (32.1)	265 (67.9)	262 (67.2)	124 (31.8)	125 (32.1)	125 (32.1)
Ewing sarcoma family of tumors	103	17 (16.5)	86 (83.5)	8 (7.8)	29 (28.2)	13 (12.6)	34 (33.0)
Osteosarcoma	132	123 (93.2)	9 (6.8)	2 (1.5)	2 (1.5)	0 (0.0)	3 (2.3)
Germ cell tumor	81	64 (79.0)	17 (21.0)	1 (1.2)	10 (12.3)	9 (11.1)	14 (17.3)
Hepatoblastoma	26	24 (92.3)	2 (7.7)	0 (0.0)	2 (7.7)	2 (7.7)	0 (0.0)
Hodgkin lymphoma	413	14 (3.4)	399 (96.6)	26 (6.3)	373 (90.3)	222 (53.8)	124 (30.0)
Non-Hodgkin lymphoma	247	149 (60.3)	98 (39.7)	53 (21.5)	47 (19.0)	29 (11.7)	31 (12.6)
Melanoma	20	18 (90.0)	2 (10.0)	1 (5.0)	1 (5.0)	0 (0.0)	0 (0.0)
Neuroblastoma	156	121 (77.6)	35 (22.4)	2 (1.3)	30 (19.2)	18 (11.5)	15 (9.6)
Retinoblastoma	102	52 (51.0)	50 (49.0)	49 (48.0)	2 (2.0)	0 (0.0)	1 (1.0)
RMS	122	22 (18.0)	100 (82.0)	51 (41.8)	22 (18.0)	15 (12.3)	42 (34.4)
Non-RMS	97	43 (44.3)	54 (55.7)	9 (9.3)	16 (16.5)	7 (7.2)	9 (9.3)
Wilms tumor	228	88 (38.6)	140 (61.4)	1 (0.4)	140 (61.4)	136 (59.6)	120 (52.6)
Carcinomas	52	20 (38.5)	32 (61.5)	29 (55.8)	5 (9.6)	1 (1.9)	2 (3.8)
Other malignancy	21	10 (47.6)	11 (52.4)	4 (19.0)	5 (23.8)	3 (14.3)	4 (19.0)
Other neoplasm	5	2 (40.0)	3 (60.0)	1 (20.0)	2 (40.0)	2 (40.0)	2 (40.0)
All Diagnoses	3482	1468	2014	1193	1032	792	734

**Study status as of April 30, 2020 **Fields are not mutually exclusive*

Table 7 Expansion Cohort. Radiation Exposure among SJLIFE Campus Visit Participants by Primary Diagnosis and Treatment Field (N=1747)*

Primary Diagnosis	Radiation Treatment Field - Potential Impact**						
	Total N	None N (%)	Any N (%)	Brain/Cranium N (%)	Chest N (%)	Abdomen N (%)	Pelvis N (%)
Acute lymphoblastic leukemia	378	339 (89.7)	39 (10.3)	36 (9.5)	30 (7.9)	30 (7.9)	30 (7.9)
Acute myeloid leukemia	113	80 (70.8)	33 (29.2)	31 (27.4)	32 (28.3)	31 (27.4)	31 (27.4)
Other leukemia	14	6 (42.9)	8 (57.1)	8 (57.1)	8 (57.1)	8 (57.1)	8 (57.1)
Other hematologic malignancy	21	18 (85.7)	3 (14.3)	3 (14.3)	1 (4.8)	1 (4.8)	1 (4.8)
CNS tumor	375	111 (29.6)	264 (70.4)	263 (70.1)	129 (34.4)	128 (34.1)	128 (34.1)
Ewing sarcoma family of tumors	30	11 (36.7)	19 (63.3)	7 (23.3)	6 (20.0)	3 (10.0)	6 (20.0)
Osteosarcoma	45	41 (91.1)	4 (8.9)	1 (2.2)	3 (6.7)	3 (6.7)	3 (6.7)
Germ cell tumor	24	23 (95.8)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.2)
Hepatoblastoma	11	11 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hodgkin lymphoma	109	18 (16.5)	91 (83.5)	1 (0.9)	88 (80.7)	35 (32.1)	19 (17.4)
Non-Hodgkin lymphoma	71	68 (95.8)	3 (4.2)	3 (4.2)	3 (4.2)	3 (4.2)	3 (4.2)
Melanoma	26	25 (96.2)	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Neuroblastoma	93	48 (51.6)	45 (48.4)	6 (6.5)	43 (46.2)	43 (46.2)	25 (26.9)
Retinoblastoma	206	158 (76.7)	48 (23.3)	48 (23.3)	1 (0.5)	1 (0.5)	1 (0.5)
RMS	48	12 (25.0)	36 (75.0)	17 (35.4)	7 (14.6)	7 (14.6)	11 (22.9)
Non-RMS	49	20 (40.8)	29 (59.2)	5 (10.2)	10 (20.4)	6 (12.2)	6 (12.2)
Wilms tumor	84	33 (39.3)	51 (60.7)	0 (0.0)	51 (60.7)	49 (58.3)	46 (54.8)
Carcinomas	20	11 (55.0)	9 (45.0)	9 (45.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other malignancy	17	11 (64.7)	6 (35.3)	1 (5.9)	2 (11.8)	2 (11.8)	4 (23.5)
Other neoplasm	13	10 (76.9)	3 (23.1)	0 (0.0)	2 (15.4)	0 (0.0)	0 (0.0)
All Diagnoses	1747	1054	693	439	416	350	323

**Study status as of April 30, 2020 **Fields are not mutually exclusive*

